Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability

Breast Cancer Research and Treatment

Volumn 62, Issue 3, 2000, Pages 217-222

  Venturino, A ^a   Comandini, D ^a   Granetto, C ^a   Audisio, R A ^a   Castiglione, F ^a   Rosso, R ^a   Repetto, L ^a  

^a Oncologia Medica   (Italy)

Author keywords

Breast cancer; Comorbidity; Disability; Elderly; Formestane; Hormonal treatment

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; FORMESTANE; TAMOXIFEN;

AGE; AGED; ARTHRITIS; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMORBIDITY; DAILY LIFE ACTIVITY; DISABILITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HORMONE DEPENDENCE; HUMAN; HYPERTENSION; INJECTION PAIN; METASTASIS; OSTEOARTHRITIS; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RISK FACTOR; SURVIVAL TIME; VASCULAR DISEASE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COMORBIDITY; ENZYME INHIBITORS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INJECTIONS, INTRAMUSCULAR; TREATMENT OUTCOME;

EID: 0033754622     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006490524736     Document Type: Article

References (46)

1. Relative survival in elderly cancer patients in Europe. EUROCARE Working Group
2. Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumour grade, and axillary lymph node status
3. Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital
4. Histopathology of breast cancer in relation to age
5. Meeting highlights: International consensus panel on the treatment of primary breast cancer
6. Combination chemoterapy compared to Tamoxifen as initial therapy for stage IV breast cancer in elderly women
7. Breast cancer, part 3
8. Towards a molecular basis for tamoxifen resistance in breast cancer
9. Effect of tamoxifen on measurements of hemostasis in healthy women
10. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial
11. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and thrombin III levels
12. The influence of tamoxifen on plasma coagulation and serous fibrinolysis
13. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study
14. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition
15. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
16. Lipoprotein profile in breast cancer women: Effect of tamoxifen treatment
17. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status
18. Changes in serum lipid and lipoprotein levels in postmenopausal patients with node-positive breast cancer treated with tamoxifen
19. Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer
20. Aromatase inhibition: Basic concept, and the pharmacodynamics of formestane
21. Aromatase inhibitors, their pharmacology and application
22. 4-Hydroxy-androstenedione treatment of postmenopausal patients with advanced breast cancer
23. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report
24. Formestane
25. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer
26. Formestane: An effective first-line endocrine treatment for advanced breast cancer
27. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions
28. Comorbidity and functional status are independent in older cancer patients
29. The impact of cancer on the physical function of the elderly and their utilization of health care
30. Cancer and the functional status of the elderly
31. Validation of a multidimensional evaulation scale for use in elderly cancer patients
32. Systemic therapy in breast cancer: Efficacy and cost utility
33. Mitoxantrone in elderly patients with advanced breast cancer: Pharmacokinetics, marrow and peripheral hematopoietic progenitor cells
34. 4-Hydroxyndrostenedione in the treatment of advanced breast cancer
35. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal breast cancer: A phase II study
36. Treatment of advanced breast cancer with formestane
37. 4-Hydroxyandrostenedione - Further clinical and extended endocrine observations
38. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer
39. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
40. Formestane as treatment of advanced breast cancer in elderly women
41. Proper sequence of endocrine therapies in advanced breast cancer
42. When tamoxifen fails in the treatment of advanced breast cancer - Which endocrine therapy comes next?
43. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis